一種比色法檢測(cè)前列腺癌的效果比前列腺特異性抗原檢測(cè)法(PSA)更加有效。

這種新方法使用化學(xué)發(fā)光法檢測(cè)alpha-胎蛋白(RECAF)，這是血清中的一種癌癥指標(biāo)。化學(xué)發(fā)光法是以標(biāo)記物與特定化學(xué)物質(zhì)接觸后能夠發(fā)光為基礎(chǔ)的，能夠用于高通量系統(tǒng)。該技術(shù)比放免法具有優(yōu)勢(shì)，放免法使用放射性同位素作為標(biāo)記物來(lái)檢測(cè)微量的RECAF。化學(xué)發(fā)光法具有更長(zhǎng)的保存時(shí)間，使用更加方便，更加容易運(yùn)輸。

2006年9月美國(guó)帕薩迪納(CA, USA)舉行的國(guó)際癌胚抗原生物學(xué)與醫(yī)學(xué)年會(huì)上，BioCurex公司(Richmond, Canada)展示了該公司使用該版本RECAF血液檢測(cè)法精細(xì)癌癥檢測(cè)的結(jié)果。

Colorimetric Assay for Prostate Cancer Offers Advantages
 
A colorimetric assay detects prostate cancer more efficiently than the prostate-specific antigen (PSA) test.

The new test uses chemoluminescence to estimate the amount of the receptor for alpha-fetoprotein (RECAF), a cancer marker, in serum. Chemoluminescence, which is based on a tag that emits light when it reacts with certain chemicals, can be used with high throughput systems. The technique has advantages over the radioimmunoassay, which uses a radioisotope as the tag to estimate trace amounts of RECAF. The colorimetric method has a longer shelf life, is more convenient, and is easier to ship.

BioCurex Inc. (Richmond, Canada), presented its first set of results using the colorimetric version of its RECAF blood test for cancer detection at the annual meeting of the International Society for Oncofetal Biology and Medicine, which was held in September 2006 in Pasadena (CA, USA).